News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,942 Results
Type
Article (14949)
Company Profile (299)
Press Release (266688)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79923)
Career Advice (170)
Deals (13345)
Drug Delivery (39)
Drug Development (50706)
Employer Resources (34)
FDA (5844)
Job Trends (5173)
News (145204)
Policy (10107)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (928)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21776)
ALS (124)
Alzheimer's disease (1031)
Antibody-drug conjugate (ADC) (242)
Approvals (6036)
Artificial intelligence (260)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4563)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3128)
Cardiovascular disease (239)
Career advice (154)
Career pathing (7)
CAR-T (217)
CDC (7)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43669)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1105)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4320)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1385)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (10)
Drug discovery (187)
Drug pricing (49)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31654)
Editorial (26)
Employer branding (4)
Employer resources (33)
Events (51702)
Executive appointments (621)
FDA (7594)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (22)
Gene therapy (486)
GLP-1 (504)
Government (1164)
Grass and pollen (3)
Guidances (166)
Healthcare (6637)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1209)
Inflammatory bowel disease (155)
Inflation Reduction Act (11)
Influenza (39)
Intellectual property (167)
Interviews (22)
IPO (7348)
IRA (12)
Job creations (869)
Job search strategy (132)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (244)
Leadership (10)
Legal (1404)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (10)
Manufacturing (375)
MASH (130)
Medical device (2669)
Medtech (2678)
Mergers & acquisitions (6620)
Metabolic disorders (725)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2051)
Non-profit (873)
Now hiring (30)
Obesity (330)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26694)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15476)
Phase 2 (20288)
Phase 3 (12820)
Pipeline (3239)
Policy (94)
Postmarket research (854)
Preclinical (6537)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1449)
Recruiting (13)
Regulatory (9914)
Reports (19)
Research institute (974)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (338)
Venture capital (69)
Weight loss (174)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1165)
Last 365 days (17808)
2026 (1651)
2025 (18110)
2024 (20563)
2023 (22426)
2022 (26884)
2021 (27836)
2020 (23399)
2019 (16265)
2018 (11773)
2017 (13754)
2016 (11851)
2015 (14366)
2014 (10407)
2013 (7493)
2012 (7538)
2011 (7628)
2010 (7435)
Location
Africa (155)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18265)
Australia (3112)
California (7076)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39180)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (738)
Massachusetts (5580)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1277)
Puerto Rico (9)
Rhode Island (25)
South America (216)
South Carolina (9)
Southern California (2807)
Tennessee (40)
Texas (904)
United States (23332)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (45)
281,942 Results for "viewpoint therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid.
July 5, 2023
·
4 min read
Deals
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
Visus Therapeutics Inc. today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics.
September 28, 2022
·
4 min read
BioMidwest
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent
Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent.
January 23, 2023
·
3 min read
Press Releases
Centerline Biomedical celebrates first on-label surgical case at the University of Virginia Health System with the 6Fr Viewpoint™ Catheter
November 20, 2024
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Defence’s Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines
September 5, 2023
·
4 min read
Vaccines
‘More Critical’ Vaccine Advisors Expected Following Kennedy’s ACIP Ouster
Robert F. Kennedy Jr.’s removal of all remaining members of the CDC’s Advisory Committee on Immunization Practices raises questions about the upcoming meeting later this month. Analysts fear the committee could be more sympathetic to the HHS Secretary’s anti-vax viewpoints.
June 10, 2025
·
3 min read
·
Heather McKenzie
Deals
Viewpoint Molecular Targeting Announces Transformational Merger
Viewpoint Molecular Targeting, Inc. today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy.
September 29, 2022
·
3 min read
Policy
Viewpoint Molecular Targeting Announces VMT-
Viewpoint Molecular Targeting, Inc. announced that the U.S. Food and Drug Administration has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors.
October 3, 2022
·
3 min read
Deals
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc.
February 6, 2023
·
5 min read
1 of 28,195
Next
